乐天堂FUN88生物宣布JS005（IL-17A单抗）治疗中重度斑块状银屑病的Ⅲ期临床研究达到共同主要研究终点和关键次要终点

>JS005在治疗中重度斑块状银屑病的一项多中心、随机、双盲、平行、安慰剂对照的关键注册性Ⅲ期临床研究中取得阳性结果

Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma

>The sNDA for toripalimab in combination with disitamab vedotin as the treatment of HER2-expressing locally advanced or metastatic UC has been accepted by the NMPA.

Junshi Biosciences Announces Ongericimab’s sNDA Approval in China

>The NMPA has recently approved ongericimab's two sNDA, becoming China’s first domestic PCSK9-targeted drug approved for statin-intolerant patients

Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma

>This marks the approval of toripalimab’s 12th indication in the Chinese mainland.